IMA

ImageneBio, Inc. Common Stock

IMA

Market cap $102M

Overview Fund Activity

9.14 USD

-0.06

0.65%

At close Updated Sep 12, 4:00 PM EDT

1 day

-0.65%

5 days

14.25%

1 month

-37.7%

3 months

-44.4%

6 months

-45.2%

Year to date

-53.84%

1 year

-55.2%

5 years

-97.62%

10 years

-97.62%

About: ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2% more capital invested

Capital invested by funds: $41.9M [Q1] → $42.6M (+$649K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

0.2% less ownership

Funds ownership: 6.51% [Q1] → 6.32% (-0.2%) [Q2]

9% less funds holding

Funds holding: 45 [Q1] → 41 (-4) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$276

2,920% upside

Avg. target

$276

2,920% upside

High target

$276

2,920% upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Wedbush

David Nierengarten

$276

Neutral

Maintained

25 Jul 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the “Board”) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (“RSUs”) for 153,505 shares of common stock (together, the “Inducement Awards”). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with ImageneBio in accordance with Nasdaq Listing Rule 5635(c)(4).

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company will operate under the name ImageneBio, Inc. (“ImageneBio”) and will trade on The Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “IMA” beginning at market open on July 28, 2025.

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

See News Rankings

Charts implemented using Lightweight Charts™